CDMOs to benefit from BTDs, orphan drugs, fast track statusThe arrival of patient-centric CDMO’s predicted by CPhI Annual Report
Frankfurt, 05th November 2019: CPhI Worldwide – the world’s largest pharma event taking place in Frankfurt (5th – 7th November 2019) – has released the fourth part of its eponymous 2019 annual Report. Experts Peter Soelkner, Managing Director, Vetter Pharma International GmbH, Stewart Needleman, Chief Commercial Officer, Piramal Pharma Solutions and Adam Bradbury, Industry Analyst, Pharmsource (a GlobalData product) discuss the future of patient centric CDMOs.
In his piece, Bradbury explores how the changing drugs pipeline and increasing diversity of innovators are creating opportunities for the CDMO sector. He asserts that the increase in drug approvals and priority reviews are likely to be beneficial to the CMO industry in the next few years, as manufacturing of these products is often outsourced.
According to Bradbury’s analysis, 23 NMEs were approved with Fast Track status in 2018. This was significantly more than in 2017. Of these products, 70% of them were outsourced,